ALIM:NSD-Alimera Sciences, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSD

Last Closing Price

USD 5.24

Change

-0.24 (-4.38)%

Market Cap

USD 0.03B

Volume

0.02M

Average Target Price

USD 14.50 (+176.72%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through sales force, as well as through distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-22 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

+0.04 (+0.27%)

USD7.85B 30.49 7.46
MNTA Momenta Pharmaceuticals, Inc

-0.01 (-0.02%)

USD6.23B N/A N/A
PCRX Pacira BioSciences, Inc

+0.73 (+1.22%)

USD2.59B 870.20 76.94
CRON Cronos Group Inc

+0.19 (+3.71%)

USD1.79B 2.50 N/A
IRWD Ironwood Pharmaceuticals, Inc

-0.02 (-0.21%)

USD1.55B 15.98 13.26
APHA Aphria Inc

+0.10 (+2.25%)

USD1.27B 57.50 435.71
ATNX Athenex, Inc

+0.32 (+2.56%)

USD1.15B N/A N/A
SUPN Supernus Pharmaceuticals, Inc

-0.35 (-1.60%)

USD1.13B 10.22 6.48
AMPH Amphastar Pharmaceuticals, Inc

-0.26 (-1.36%)

USD0.90B 243.13 29.78
PETQ PetIQ, Inc

-0.74 (-2.48%)

USD0.85B 134.36 112.85

ETFs Containing ALIM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -30.87% 47% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.87% 47% F 26% F
Trailing 12 Months  
Capital Gain -41.78% 40% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -41.78% 40% F 16% F
Trailing 5 Years  
Capital Gain -86.25% 16% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -86.25% 16% F 8% F
Average Annual (5 Year Horizon)  
Capital Gain -28.83% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -28.83% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 25.48% N/A N/A N/A N/A
Risk Adjusted Return -113.15% N/A N/A N/A N/A
Market Capitalization 0.03B 13% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1.13 87% B+ 90% A-
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -6.75 74% C 77% C+
EV/EBITDA 69.96 23% F 10% F
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -14.68% 60% D- 31% F
Return on Assets -1.94% 72% C- 38% F
Debt to Equity Ratio -869.70% 88% B+ 99% A+
Technical Ratios  
Short Ratio 0.35 89% B+ 86% B
Short Percent 0.76% 91% A- 83% B
Beta 2.05 17% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.